{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:52:18Z","timestamp":1794009138004,"version":"4.8.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["201903010092"],"award-info":[{"award-number":["201903010092"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Acute exacerbation (AE) is a devastating complication of rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and leads to high mortality. This study aimed to investigate the incidence, risk factors, and prognosis of acute exacerbation of rheumatoid arthritis-associated interstitial lung disease (AE-RA-ILD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>PubMed, EMBASE, Web of Science, and Medline were searched through 8 February 2023. Two independent researchers selected eligible articles and extracted available data. The Newcastle Ottawa Scale was used to assess the methodological quality of studies used for meta-analysis. The incidence and prognosis of AE-RA-ILD were investigated. Weighted mean differences (WMDs) with corresponding 95% confidence intervals (CIs) and pooled odds ratios (ORs) with 95% CIs were calculated to explore the risk factors of AE in RA-ILD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-one of 1,589 articles were eligible. A total of 385 patients with AE-RA-ILD, of whom 53.5% were male, were included. The frequency of AE in patients with RA-ILD ranged from 6.3 to 55.6%. The 1-year and 5-year AE incidences were 2.6\u201311.1% and 11\u201329.4%, respectively. The all-cause mortality rate of AE-RA-ILD was 12.6\u201327.9% at 30 days and 16.7\u201348.3% at 90 days. Age at RA diagnosis (WMD: 3.61, 95% CI: 0.22\u20137.01), male sex (OR: 1.60, 95% CI:1.16\u20132.21), smoking (OR: 1.50, 95% CI: 1.08\u20132.08), lower forced vital capacity predicted (FVC%; WMD: \u22128.63, 95% CI: \u221214.68 to \u2212\u20092.58), and definite usual interstitial pneumonia (UIP) pattern (OR: 1.92, 95% CI: 1.15\u20133.22) were the risk factors of AE-RA-ILD. Moreover, the use of corticosteroids, methotrexate, and biological disease-modifying anti-rheumatic drugs, was not associated with AE-RA-ILD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>AE-RA-ILD was not rare and had a poor prognosis. Age at RA diagnosis, male sex, smoking, lower FVC%, and definite UIP pattern increased the risk of AE-RA-ILD. The use of medications, especially methotrexate and biological disease-modifying anti-rheumatic drugs, may not be related to AE-RA-ILD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Registration<\/jats:title>\n                <jats:p>CRD42023396772.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-023-02532-2","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T12:01:45Z","timestamp":1689076905000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Incidence, risk factors, and prognosis of acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Maosheng","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"key":"2532_CR1","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.","journal-title":"Nat Rev Dis Primers"},{"key":"2532_CR2","doi-asserted-by":"crossref","unstructured":"Shaw M, Collins BF, Ho LA, Raghu G. Rheumatoid arthritis-associated lung disease. Eur Respiratory Review: Official J Eur Respiratory Soc 2015, 24(135).","DOI":"10.1183\/09059180.00008014"},{"issue":"6","key":"2532_CR3","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/art.27405","volume":"62","author":"T Bongartz","year":"2010","unstructured":"Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, Vassallo R, Gabriel SE, Matteson EL. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62(6):1583\u201391.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2532_CR4","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1183\/13993003.00357-2015","volume":"47","author":"JJ Solomon","year":"2016","unstructured":"Solomon JJ, Chung JH, Cosgrove GP, Demoruelle MK, Fernandez-Perez ER, Fischer A, Frankel SK, Hobbs SB, Huie TJ, Ketzer J, et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2016;47(2):588\u201396.","journal-title":"Eur Respir J"},{"issue":"4","key":"2532_CR5","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3899\/jrheum.171315","volume":"46","author":"K Raimundo","year":"2019","unstructured":"Raimundo K, Solomon JJ, Olson AL, Kong AM, Cole AL, Fischer A, Swigris JJ. Rheumatoid arthritis-interstitial lung disease in the United States: prevalence, incidence, and Healthcare costs and mortality. J Rheumatol. 2019;46(4):360\u20139.","journal-title":"J Rheumatol"},{"key":"2532_CR6","doi-asserted-by":"crossref","unstructured":"Joo YB, Ahn SM, Bang S-Y, Park Y, Hong SJ, Lee Y, Cho S-K, Choi C-B, Sung Y-K, Kim T-H et al. MUC5B promoter variant rs35705950, rare but significant susceptibility locus in rheumatoid arthritis-interstitial lung disease with usual interstitial pneumonia in asian populations. RMD Open 2022, 8(2).","DOI":"10.1136\/rmdopen-2022-002790"},{"issue":"6","key":"2532_CR7","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1183\/09031936.00092309","volume":"35","author":"EJ Kim","year":"2010","unstructured":"Kim EJ, Elicker BM, Maldonado F, Webb WR, Ryu JH, Van Uden JH, Lee JS, King TE, Collard HR. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35(6):1322\u20138.","journal-title":"Eur Respir J"},{"issue":"5","key":"2532_CR8","doi-asserted-by":"publisher","first-page":"103056","DOI":"10.1016\/j.autrev.2022.103056","volume":"21","author":"M Akiyama","year":"2022","unstructured":"Akiyama M, Kaneko Y. Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease. Autoimmun Rev. 2022;21(5):103056.","journal-title":"Autoimmun Rev"},{"issue":"6","key":"2532_CR9","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1378\/chest.103.6.1808","volume":"103","author":"Y Kondoh","year":"1993","unstructured":"Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest. 1993;103(6):1808\u201312.","journal-title":"Chest"},{"issue":"7","key":"2532_CR10","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1164\/rccm.200703-463PP","volume":"176","author":"HR Collard","year":"2007","unstructured":"Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE, Lasky JA, Loyd JE, Noth I, Olman MA, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(7):636\u201343.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"2532_CR11","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.21037\/jtd.2019.03.28","volume":"11","author":"A Manfredi","year":"2019","unstructured":"Manfredi A, Sebastiani M, Cerri S, Vacchi C, Tonelli R, Casa GD, Cassone G, Spinella A, Fabrizio P, Luppi F, et al. Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: a prospective study and review of the literature. J Thorac Disease. 2019;11(4):1621\u20138.","journal-title":"J Thorac Disease"},{"issue":"1","key":"2532_CR12","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12890-021-01502-w","volume":"21","author":"H Kamiya","year":"2021","unstructured":"Kamiya H, Panlaqui OM. A systematic review of the incidence, risk factors and prognosis of acute exacerbation of systemic autoimmune disease-associated interstitial lung disease. BMC Pulm Med. 2021;21(1):150.","journal-title":"BMC Pulm Med"},{"key":"2532_CR13","doi-asserted-by":"crossref","unstructured":"Solomon JJ, Danoff SK, Woodhead FA, Hurwitz S, Maurer R, Glaspole I, Dellaripa PF, Gooptu B, Vassallo R, Cox PG, et al. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. The Lancet Respiratory medicine; 2022.","DOI":"10.1101\/2022.04.01.22273270"},{"key":"2532_CR14","doi-asserted-by":"crossref","unstructured":"Luppi F, Sebastiani M, Sverzellati N, Cavazza A, Salvarani C, Manfredi A. Lung complications of Sjogren syndrome. Eur Respiratory Review: Official J Eur Respiratory Soc 2020, 29(157).","DOI":"10.1183\/16000617.0021-2020"},{"issue":"7","key":"2532_CR15","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1164\/ajrccm.164.7.2103110","volume":"164","author":"WW Douglas","year":"2001","unstructured":"Douglas WW, Tazelaar HD, Hartman TE, Hartman RP, Decker PA, Schroeder DR, Ryu JH. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med. 2001;164(7):1182\u20135.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"2532_CR16","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1164\/rccm.2106012","volume":"165","author":"D Bouros","year":"2002","unstructured":"Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, Haslam PL, Vassilakis DA, Black CM, du Bois RM. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002;165(12):1581\u20136.","journal-title":"Am J Respir Crit Care Med"},{"key":"2532_CR17","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151(4).","DOI":"10.7326\/0003-4819-151-4-200908180-00136"},{"issue":"3","key":"2532_CR18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS. The american Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315\u201324.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"2532_CR19","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"2532_CR20","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1164\/rccm.200607-912OC","volume":"175","author":"JH Park","year":"2007","unstructured":"Park JH, Kim DS, Park IN, Jang SJ, Kitaichi M, Nicholson AG, Colby TV. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med. 2007;175(7):705\u201311.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"2532_CR21","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier J-F, Flaherty KR, Lasky JA, et al. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788\u2013824.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2532_CR22","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, et al. Diagnosis of idiopathic pulmonary fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198(5):e44\u2013e68.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"2532_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41584-021-00721-z","volume":"18","author":"F Luppi","year":"2022","unstructured":"Luppi F, Sebastiani M, Salvarani C, Bendstrup E, Manfredi A. Acute exacerbation of interstitial lung disease associated with rheumatic disease. Nat Rev Rheumatol. 2022;18(2):85\u201396.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"2532_CR24","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.semarthrit.2021.07.008","volume":"51","author":"K Nakamura","year":"2021","unstructured":"Nakamura K, Ohbe H, Ikeda K, Uda K, Furuya H, Furuta S, Nakajima M, Sasabuchi Y, Matsui H, Fushimi K, et al. Intravenous cyclophosphamide in acute exacerbation of rheumatoid arthritis-related interstitial lung disease: a propensity-matched analysis using a nationwide inpatient database. Semin Arthritis Rheum. 2021;51(5):977\u201382.","journal-title":"Semin Arthritis Rheum"},{"key":"2532_CR25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"2532_CR26","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/crj.12631","volume":"12","author":"M Qiu","year":"2018","unstructured":"Qiu M, Chen Y, Ye Q. Risk factors for acute exacerbation of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Clin Respir J. 2018;12(3):1084\u201392.","journal-title":"Clin Respir J"},{"key":"2532_CR27","first-page":"ED000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for systematic reviews of interventions. Cochrane Database Syst Rev. 2019;10:ED000142.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"2532_CR28","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1080\/14397595.2021.1879346","volume":"31","author":"N Tanaka","year":"2021","unstructured":"Tanaka N, Nishimura K, Waki D, Kadoba K, Murabe H, Yokota T. Annual variation rate of KL-6 for predicting acute exacerbation in patients with rheumatoid arthritis-associated interstitial lung disease. Mod Rheumatol. 2021;31(6):1100\u20136.","journal-title":"Mod Rheumatol"},{"key":"2532_CR29","doi-asserted-by":"crossref","unstructured":"Otsuka J, Yoshizawa S, Kudo K, Osoreda H, Ishimatsu A, Taguchi K, Moriwaki A, Wakamatsu K, Iwanaga T, Yoshida M. Clinical features of acute exacerbation in rheumatoid arthritis\u2013associated interstitial lung disease: comparison with idiopathic pulmonary fibrosis. Respir Med 2022, 200.","DOI":"10.1016\/j.rmed.2022.106898"},{"issue":"1","key":"2532_CR30","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.chest.2022.01.007","volume":"162","author":"BS Kwon","year":"2022","unstructured":"Kwon BS, Lee HY, Choe J, Chae EJ, Hong S, Song JW. Acute Respiratory Deterioration in Rheumatoid Arthritis-Associated interstitial lung disease: a single-center study. Chest. 2022;162(1):136\u201344.","journal-title":"Chest"},{"issue":"5","key":"2532_CR31","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1093\/rheumatology\/keaa608","volume":"60","author":"S Izuka","year":"2021","unstructured":"Izuka S, Yamashita H, Iba A, Takahashi Y, Kaneko H. Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: clinical features and prognosis. Rheumatology (Oxford). 2021;60(5):2348\u201354.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"2532_CR32","doi-asserted-by":"publisher","first-page":"e003132","DOI":"10.1136\/bmjopen-2013-003132","volume":"3","author":"H Hozumi","year":"2013","unstructured":"Hozumi H, Nakamura Y, Johkoh T, Sumikawa H, Colby TV, Kono M, Hashimoto D, Enomoto N, Fujisawa T, Inui N, et al. Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study. BMJ Open. 2013;3(9):e003132.","journal-title":"BMJ Open"},{"issue":"6","key":"2532_CR33","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00296-016-3478-3","volume":"36","author":"M Akiyama","year":"2016","unstructured":"Akiyama M, Kaneko Y, Yamaoka K, Kondo H, Takeuchi T. Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case\u2013control study. Rheumatol Int. 2016;36(6):881\u20139.","journal-title":"Rheumatol Int"},{"issue":"12","key":"2532_CR34","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.21037\/jtd.2019.11.73","volume":"11","author":"H Yamakawa","year":"2019","unstructured":"Yamakawa H, Sato S, Tsumiyama E, Nishizawa T, Kawabe R, Oba T, Kamikawa T, Horikoshi M, Akasaka K, Amano M, et al. Predictive factors of mortality in rheumatoid arthritis-associated interstitial lung disease analysed by modified HRCT classification of idiopathic pulmonary fibrosis according to the 2018 ATS\/ERS\/JRS\/ALAT criteria. J Thorac Dis. 2019;11(12):5247\u201357.","journal-title":"J Thorac Dis"},{"issue":"5","key":"2532_CR35","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/resp.13682","volume":"25","author":"A Suzuki","year":"2020","unstructured":"Suzuki A, Kondoh Y, Brown KK, Johkoh T, Kataoka K, Fukuoka J, Kimura T, Matsuda T, Yokoyama T, Fukihara J, et al. Acute exacerbations of fibrotic interstitial lung diseases. Respirol (Carlton Vic). 2020;25(5):525\u201334.","journal-title":"Respirol (Carlton Vic)"},{"issue":"1","key":"2532_CR36","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1378\/chest.07-0323","volume":"132","author":"IN Park","year":"2007","unstructured":"Park IN, Kim DS, Shiin TS, Lim C-M, Do Lee S, Koh Y, Kim WS, Kim WD, Jang SJ, Colby TV. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest. 2007;132(1):214\u201320.","journal-title":"Chest"},{"issue":"6","key":"2532_CR37","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.rmed.2008.12.019","volume":"103","author":"T Suda","year":"2009","unstructured":"Suda T, Kaida Y, Nakamura Y, Enomoto N, Fujisawa T, Imokawa S, Hashizume H, Naito T, Hashimoto D, Takehara Y, et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir Med. 2009;103(6):846\u201353.","journal-title":"Respir Med"},{"issue":"1","key":"2532_CR38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000329893","volume":"83","author":"R Tachikawa","year":"2012","unstructured":"Tachikawa R, Tomii K, Ueda H, Nagata K, Nanjo S, Sakurai A, Otsuka K, Kaji R, Hayashi M, Katakami N, et al. Clinical features and outcome of acute exacerbation of interstitial pneumonia: collagen vascular diseases-related versus idiopathic. Respiration. 2012;83(1):20\u20137.","journal-title":"Respiration"},{"issue":"1","key":"2532_CR39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12931-022-01978-y","volume":"23","author":"H Hozumi","year":"2022","unstructured":"Hozumi H, Kono M, Hasegawa H, Kato S, Inoue Y, Suzuki Y, Karayama M, Furuhashi K, Enomoto N, Fujisawa T, et al. Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: mortality and its prediction model. Respir Res. 2022;23(1):57.","journal-title":"Respir Res"},{"issue":"1","key":"2532_CR40","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1183\/09031936.06.00114004","volume":"27","author":"DS Kim","year":"2006","unstructured":"Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J. 2006;27(1):143\u201350.","journal-title":"Eur Respir J"},{"issue":"2","key":"2532_CR41","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1183\/09031936.00159709","volume":"37","author":"JW Song","year":"2011","unstructured":"Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011;37(2):356\u201363.","journal-title":"Eur Respir J"},{"issue":"1","key":"2532_CR42","doi-asserted-by":"publisher","first-page":"9120","DOI":"10.1038\/s41598-021-88718-2","volume":"11","author":"T Suzuki","year":"2021","unstructured":"Suzuki T, Hozumi H, Miyashita K, Kono M, Suzuki Y, Karayama M, Furuhashi K, Hasegawa H, Fujisawa T, Enomoto N, et al. Prognostic classification in acute exacerbation of idiopathic pulmonary fibrosis: a multicentre retrospective cohort study. Sci Rep. 2021;11(1):9120.","journal-title":"Sci Rep"},{"key":"2532_CR43","doi-asserted-by":"crossref","first-page":"147997231880947","DOI":"10.1177\/1479972318809476","volume":"16","author":"N Enomoto","year":"2019","unstructured":"Enomoto N, Oyama Y, Enomoto Y, Yasui H, Karayama M, Kono M, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, et al. Differences in clinical features of acute exacerbation between connective tissue disease-associated interstitial pneumonia and idiopathic pulmonary fibrosis. Chronic Resp Dis. 2019;16:1479972318809476.","journal-title":"Chronic Resp Dis"},{"key":"2532_CR44","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.rmed.2017.05.009","volume":"128","author":"G Ishikawa","year":"2017","unstructured":"Ishikawa G, Acquah SO, Salvatore M, Padilla ML. Elevated serum D-dimer level is associated with an increased risk of acute exacerbation in interstitial lung disease. Respir Med. 2017;128:78\u201384.","journal-title":"Respir Med"},{"issue":"3\u20134","key":"2532_CR45","doi-asserted-by":"publisher","first-page":"294","DOI":"10.2152\/jmi.63.294","volume":"63","author":"Y Toyoda","year":"2016","unstructured":"Toyoda Y, Hanibuchi M, Kishi J, Kawano H, Morizumi S, Sato S, Kondo M, Takikura T, Tezuka T, Goto H, et al. Clinical features and outcome of acute exacerbation of interstitial pneumonia associated with connective tissue disease. J Med Invest. 2016;63(3\u20134):294\u20139.","journal-title":"J Med Invest"},{"key":"2532_CR46","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fmed.2020.00012","volume":"7","author":"J Liang","year":"2020","unstructured":"Liang J, Cao H, Ke Y, Sun C, Chen W, Lin J. Acute Exacerbation of interstitial lung disease in adult patients with idiopathic inflammatory myopathies: a retrospective case-control study. Front Med (Lausanne). 2020;7:12.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"2532_CR47","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12931-021-01856-z","volume":"22","author":"M Qiu","year":"2021","unstructured":"Qiu M, Jiang J, Nian X, Wang Y, Yu P, Song J, Zou S. Factors associated with mortality in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis. Respir Res. 2021;22(1):264.","journal-title":"Respir Res"},{"issue":"1","key":"2532_CR48","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1186\/s12890-022-02197-3","volume":"22","author":"N Enomoto","year":"2022","unstructured":"Enomoto N, Naoi H, Mochizuka Y, Isayama T, Tanaka Y, Fukada A, Aono Y, Katsumata M, Yasui H, Mori K, et al. Frequency, proportion of PF-ILD, and prognostic factors in patients with acute exacerbation of ILD related to systemic autoimmune diseases. BMC Pulm Med. 2022;22(1):387.","journal-title":"BMC Pulm Med"},{"key":"2532_CR49","doi-asserted-by":"publisher","first-page":"152004","DOI":"10.1016\/j.semarthrit.2022.152004","volume":"55","author":"N Chen","year":"2022","unstructured":"Chen N, Diao C-Y, Gao J, Zhao D-B. Risk factors for the progression of rheumatoid arthritis-related interstitial lung disease: clinical features, biomarkers, and treatment options. Semin Arthritis Rheum. 2022;55:152004.","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"2532_CR50","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41584-019-0275-x","volume":"15","author":"D Wang","year":"2019","unstructured":"Wang D, Zhang J, Lau J, Wang S, Taneja V, Matteson EL, Vassallo R. Mechanisms of lung disease development in rheumatoid arthritis. Nat Rev Rheumatol. 2019;15(10):581\u201396.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"2532_CR51","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12890-019-0960-1","volume":"19","author":"M Cao","year":"2019","unstructured":"Cao M, Sheng J, Qiu X, Wang D, Wang D, Wang Y, Xiao Y, Cai H. Acute exacerbations of fibrosing interstitial lung disease associated with connective tissue diseases: a population-based study. BMC Pulm Med. 2019;19(1):215.","journal-title":"BMC Pulm Med"},{"issue":"4","key":"2532_CR52","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s10067-021-05984-1","volume":"41","author":"S-H He","year":"2022","unstructured":"He S-H, He Y-J, Guo K-J, Liang X, Li S-S, Li T-F. Risk factors for progression of interstitial lung disease in Sj\u00f6gren\u2019s syndrome: a single-centered, retrospective study. Clin Rheumatol. 2022;41(4):1153\u201361.","journal-title":"Clin Rheumatol"},{"issue":"8","key":"2532_CR53","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/1756-185X.13881","volume":"23","author":"C He","year":"2020","unstructured":"He C, Chen Z, Liu S, Chen H, Zhang F. Prevalence and risk factors of interstitial lung disease in patients with primary Sj\u00f6gren\u2019s syndrome: a systematic review and meta-analysis. Int J Rheum Dis. 2020;23(8):1009\u201318.","journal-title":"Int J Rheum Dis"},{"key":"2532_CR54","doi-asserted-by":"crossref","unstructured":"Chang SH, Lee JS, Ha Y-J, Kim MU, Park CH, Lee JS, Kim J-W, Chung SW, Pyo JY, Lee SW et al. Lung function trajectory of rheumatoid arthritis-associated interstitial lung disease. Rheumatology (Oxford) 2023.","DOI":"10.1093\/rheumatology\/kead027"},{"issue":"4","key":"2532_CR55","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/art.38322","volume":"66","author":"R Conway","year":"2014","unstructured":"Conway R, Low C, Coughlan RJ, O\u2019Donnell MJ, Carey JJ. Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis & Rheumatology (Hoboken NJ). 2014;66(4):803\u201312.","journal-title":"Arthritis & Rheumatology (Hoboken NJ)"},{"issue":"2","key":"2532_CR56","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1001\/archinternmed.2007.59","volume":"168","author":"BR Gochuico","year":"2008","unstructured":"Gochuico BR, Avila NA, Chow CK, Novero LJ, Wu H-P, Ren P, MacDonald SD, Travis WD, Stylianou MP, Rosas IO. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008;168(2):159\u201366.","journal-title":"Arch Intern Med"},{"issue":"1","key":"2532_CR57","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10067-011-1758-6","volume":"31","author":"N Sathi","year":"2012","unstructured":"Sathi N, Chikura B, Kaushik VV, Wiswell R, Dawson JK. How common is methotrexate pneumonitis? A large prospective study investigates. Clin Rheumatol. 2012;31(1):79\u201383.","journal-title":"Clin Rheumatol"},{"key":"2532_CR58","doi-asserted-by":"publisher","first-page":"175346662211353","DOI":"10.1177\/17534666221135314","volume":"16","author":"K Kim","year":"2022","unstructured":"Kim K, Woo A, Park Y, Yong SH, Lee SH, Lee SH, Leem AY, Kim SY, Chung KS, Kim EY, et al. Protective effect of methotrexate on lung function and mortality in rheumatoid arthritis-related interstitial lung disease: a retrospective cohort study. Ther Adv Respir Dis. 2022;16:17534666221135314.","journal-title":"Ther Adv Respir Dis"},{"key":"2532_CR59","doi-asserted-by":"publisher","first-page":"152031","DOI":"10.1016\/j.semarthrit.2022.152031","volume":"55","author":"J Xu","year":"2022","unstructured":"Xu J, Xiao L, Zhu J, Qin Q, Fang Y, Zhang J-A. Methotrexate use reduces mortality risk in rheumatoid arthritis: a systematic review and meta-analysis of cohort studies. Semin Arthritis Rheum. 2022;55:152031.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"2532_CR60","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/14712598.2017.1287169","volume":"17","author":"J Chen","year":"2017","unstructured":"Chen J, Chi S, Li F, Yang J, Cho WC, Liu X. Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies. Expert Opin Biol Ther. 2017;17(3):265\u201383.","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"2532_CR61","doi-asserted-by":"publisher","first-page":"e035420","DOI":"10.1136\/bmjopen-2019-035420","volume":"10","author":"H Kamiya","year":"2020","unstructured":"Kamiya H, Panlaqui OM. Systematic review and meta-analysis of prognostic factors of acute exacerbation of idiopathic pulmonary fibrosis. BMJ Open. 2020;10(6):e035420.","journal-title":"BMJ Open"},{"key":"2532_CR62","doi-asserted-by":"crossref","unstructured":"Collard HR, Richeldi L, Kim DS, Taniguchi H, Tschoepe I, Luisetti M, Roman J, Tino G, Schlenker-Herceg R, Hallmann C et al. Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Eur Respir J 2017, 49(5).","DOI":"10.1183\/13993003.01339-2016"},{"issue":"18","key":"2532_CR63","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, et al. Nintedanib in Progressive Fibrosing interstitial lung Diseases. N Engl J Med. 2019;381(18):1718\u201327.","journal-title":"N Engl J Med"},{"key":"2532_CR64","doi-asserted-by":"publisher","first-page":"1759720X2210744","DOI":"10.1177\/1759720X221074457","volume":"14","author":"M Liang","year":"2022","unstructured":"Liang M, Matteson EL, Abril A, Distler JHW. The role of antifibrotics in the treatment of rheumatoid arthritis-associated interstitial lung disease. Ther Adv Musculoskelet Dis. 2022;14:1759720X221074457.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"3","key":"2532_CR65","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/01.rti.0000213588.52343.13","volume":"22","author":"CIS Silva","year":"2007","unstructured":"Silva CIS, M\u00fcller NL, Fujimoto K, Kato S, Ichikado K, Taniguchi H, Kondoh Y, Johkoh T, Churg A. Acute exacerbation of chronic interstitial pneumonia: high-resolution computed tomography and pathologic findings. J Thorac Imaging. 2007;22(3):221\u20139.","journal-title":"J Thorac Imaging"},{"issue":"2","key":"2532_CR66","first-page":"103","volume":"30","author":"JW Song","year":"2013","unstructured":"Song JW, Lee HK, Lee CK, Chae EJ, Jang SJ, Colby TV, Kim DS. \u00ef\u00bb\u00bfClinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(2):103\u201312.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"1","key":"2532_CR67","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3109\/14397595.2016.1173816","volume":"27","author":"M Ota","year":"2017","unstructured":"Ota M, Iwasaki Y, Harada H, Sasaki O, Nagafuchi Y, Nakachi S, Sumitomo S, Shoda H, Tohma S, Fujio K, et al. Efficacy of intensive immunosuppression in exacerbated rheumatoid arthritis-associated interstitial lung disease. Mod Rheumatol. 2017;27(1):22\u20138.","journal-title":"Mod Rheumatol"},{"issue":"9","key":"2532_CR68","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1111\/1756-185X.13666","volume":"22","author":"P Singh","year":"2019","unstructured":"Singh P, Thakur B, Mohapatra AK, Padhan P. Clinical features and outcome of acute exacerbation in connective tissue disease-associated interstitial lung disease: a single-center study from India. Int J Rheum Dis. 2019;22(9):1741\u20135.","journal-title":"Int J Rheum Dis"},{"key":"2532_CR69","doi-asserted-by":"crossref","unstructured":"Wang N, Zhang Q, Ling X, Guo T, Huang H, Xu Z. The Association between MUC5B mutations and clinical outcome in patients with Rheumatoid Arthritis-Associated interstitial lung disease: a retrospective exploratory study in China. Med Sci Monit 2020, 26.","DOI":"10.12659\/MSM.920137"},{"issue":"2","key":"2532_CR70","doi-asserted-by":"publisher","first-page":"178","DOI":"10.4103\/atm.atm_14_21","volume":"16","author":"E Alhamad","year":"2021","unstructured":"Alhamad E, Cal J, Alrajhi N, Alboukai A. Acute exacerbation in interstitial lung disease. Annals of Thoracic Medicine. 2021;16(2):178\u201387.","journal-title":"Annals of Thoracic Medicine"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02532-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-023-02532-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02532-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T13:01:45Z","timestamp":1689080505000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-023-02532-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2532"],"URL":"https:\/\/doi.org\/10.1186\/s12890-023-02532-2","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,11]]},"assertion":[{"value":"9 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"255"}}